Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06642272 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record

Study acronym: APPLE TREE
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 3 words
  2. Start date: Aug 31, 2024 to Oct 10, 2024
    • Study sites: 1 to 12
    • Primary endpoint revised
    • Eligibility criteria shortened, about 1 word
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Herlev and Gentofte Hospital
36 trials monitored
See 1 trial at risk
Heart Disease
8,786 trials monitored
See 412 trials at risk
Diabetes
5,087 trials monitored
See 222 trials at risk
Type 2 Diabetes
2,231 trials monitored
See 111 trials at risk
and 2 more diseases
The aim of this clinical trial is investigate the comparative effectiveness of empagliflozin and dapagliflozin for the treatment of diabetes, chronic kidney disease, and heart failure. Patients who are prescribed either empagliflozin or dapagliflozin, as part of daily clinical practice at the participating sites, will be included in the study. Treatment will be randomized automatically through the electronic health record software in clusters defined by time of day. https://www.appletreestudy.com
Trial Details
NCT Number NCT06642272
Lead Sponsor Herlev and Gentofte Hospital
Conditions
(from sponsor)		 Diabetes Mellitus, Type 2, Heart Failure, Chronic Kidney Diseases
Related terms Diabetes Mellitus, Type 2, Heart Failure, Renal Insufficiency, Chronic
Enrollment 17,200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov